Quarterly ResultMay 15, 2026, 07:32 AM
MiNK Therapeutics Initiates Phase 2 Trial for agenT-797
AI Summary
MiNK Therapeutics initiated a randomized Phase 2 trial for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026. The company also reported Q1 2026 financial results, including a net loss of $2.7 million and cash and cash equivalents of $9.5 million. Recent data presentations at AACR and ASGCT strengthened the biologic rationale for agenT-797, and non-dilutive collaborations expanded the platform. An upcoming presentation at the ATS conference on May 20, 2026, will feature new clinical data.
Key Highlights
- Randomized Phase 2 trial for agenT-797 initiated in acute lung injury and critical illness.
- Preliminary data from agenT-797 Phase 2 trial expected in the second half of 2026.
- Q1 2026 net loss was approximately $2.7 million, or $0.57 per share.
- Cash and cash equivalents stood at approximately $9.5 million as of March 31, 2026.
- Repaid approximately $5.2 million associated with the Agenus convertible note.
- Raised approximately $3.0 million through at-the-market sales in Q1 2026.
- Collaboration with C-Further provides up to $1.1 million in non-dilutive funding.
- AACR Phase 2 data showed a 77% disease control rate in PD-1 refractory gastroesophageal cancer.
Price Impact
More from INKT